Acceleron Pharma Inc.
Apr 6, 2017

Acceleron Announces Clinical Presentations on Luspatercept at the 14th International Symposium on Myelodysplastic Syndromes

Oral presentation highlights new Phase 2 data in additional sub-populations of lower-risk MDS

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that two abstracts on luspatercept have been accepted for presentation at the 14th International Symposium on Myelodysplastic Syndromes (MDS) in Valencia, Spain on May 3-6, 2017.

The oral presentation will include data from a Phase 2 study with luspatercept in lower-risk MDS populations, including first-line ring sideroblast-negative and -positive subpopulations. Luspatercept is being developed under a global partnership with Celgene.

Oral presentation

Title:    

Luspatercept Response in New Subpopulations of Patients with Lower-Risk Myelodysplastic Syndromes (MDS): Update of the PACE Study (Abstract #17-0245)

Session: Oral Session 3 (Valencia Conference Center, Auditorium 1)
Date: Saturday, May 6th
Time:

9:15 a.m. CEST

Poster presentation

Title:    

Pharmacokinetics and Exposure-Response Relationship of Luspatercept in Patients with Anemia Due to Lower-Risk MDS: Preliminary Results from Phase 2 Studies (Abstract #17-0112)

Session: 637. Myelodysplastic Syndromes - Clinical Studies: Poster I (Valencia Conference Center)
Date: Thursday, May 4th to Saturday, May 6th

The luspatercept clinical poster and slides from the oral presentation will be available immediately following the presentations at the conference in the "Science" section on Acceleron's website, www.acceleronpharma.com.

About Luspatercept

Luspatercept is a modified activin receptor type IIB fusion protein that acts as a ligand trap for members in the Transforming Growth Factor-Beta (TGF-beta) superfamily involved in the late stages of erythropoiesis (red blood cell production). Luspatercept regulates late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation. This mechanism of action is distinct from that of erythropoietin (EPO), which stimulates the proliferation of early-stage erythrocyte precursor cells. Acceleron and Celgene are jointly developing luspatercept as part of a global collaboration. Phase 3 clinical trials are underway to evaluate the safety and efficacy of luspatercept in patients with myelodysplastic syndromes (the "MEDALIST" study) and in patients with beta-thalassemia (the "BELIEVE" study). For more information, please visit www.clinicaltrials.gov.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. Its pioneering research platform leverages the powerful biology behind the body's ability to rebuild and repair its own cells and tissues. This approach to drug discovery has generated four therapeutic candidates that are currently in clinical trials. The Company's lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases, myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on social media: @AcceleronPharma and LinkedIn.

Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
Senior Director, Investor Relations and Corporate Communications
or
Media:
BMC Communications
Brad Miles, 646-513-3125

Source: Acceleron Pharma Inc.

News Provided by Acquire Media